- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Sequenta's MRD Detection Test Predicts Post-Transplant Relapse and Survival in ALL
Sequenta's ClonoSIGHT that uses next generation sequencing to detect minimal residual disease, provides prognosis on relapse and survival of post-transplant ALL patients.
Sequenta, Inc. and collaborators have published results demonstrating that the company’s next-generation sequencing-based minimal residual disease (MRD) quantification technology, available clinically as the ClonoSIGHT™ test, provides important prognostic information about adult patients with acute lymphoblastic leukemia (ALL) who receive donor stem cell transplants. Analysis of post-transplant blood samples with Sequenta’s method predicted both relapse and survival and detected evidence of disease a median of three months prior to clinical relapse.
“Minimal residual disease testing has become a standard of care in the management of pediatric ALL, but routine assessment of MRD in adult patients remains uncommon due to the varied diagnostic capabilities of hospitals across the country and the usual requirement for bone marrow samples,” said Aaron Logan, M.D., Ph.D., Assistant Professor, UCSF School of Medicine, lead author of the study. “The ClonoSIGHT test has the advantages of being standardized and sufficiently sensitive to detect MRD in blood samples, making it a powerful tool for assessing responses to treatment and for studying methods to improve patient outcomes by intervening on progressive MRD instead of awaiting overt relapse.”
Read the press release here: http://yhoo.it/1hHfMpI
Source: Yahoo! finance
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Texas Oncology to Roll Out Canopy for ePROs After Head-to-Head Pilot
March 18th 2025Debra Patt, MD, PhD, MBA, executive vice president of Public Policy and Strategy for Texas Oncology, said the practice received positive feedback from nurses and patients during a pilot that concluded in February.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
